Navigation Links
FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
Date:8/6/2014

hed agreement with the FDA on a Special Protocol Assessment (SPA) for the PERSIST-2 trial, which is a written agreement between CTI and the FDA regarding the planned design, endpoints and statistical analysis approach of the trial to be used in support of a potential NDA submission. Under the SPA, the agreed upon co-primary endpoints are the percentage of patients achieving a 35 percent or greater reduction in spleen volume measured by MRI or CT scan from baseline to 24 weeks of treatment and the percentage of patients achieving a Total Symptom Score (TSS) reduction of 50 percent or greater using six key symptoms as measured by the modified Myeloproliferative Neoplasm Symptom Assessment (MPN-SAF TSS 2.0) diary from baseline to 24 weeks.

More details on the PERSIST-1 and PERSIST-2 trials can be found at www.clinicaltrials.gov.

About Pacritinib

Pacritinib is an oral tyrosine kinase inhibitor with dual activity against JAK2 and FLT3. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. Pacritinib may offer an advantage over other JAK inhibitors through effective treatment of symptoms while having less treatment-emergent thrombocytopenia and anemia than has been seen in currently approved and in-development JAK inhibitors.

In November 2013, CTI and Baxter International (Baxter) entered into a worldwide license agreement to develop and commercialize pacritinib in which CTI and Baxter will jointly commercialize pacritinib in the U.S. and Baxter has exclusive commercialization rights for all indications outside the U.S.

About Myelofi
'/>"/>

SOURCE CTI BioPharma
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2. US Patent Office Grants McCord Research Endothelial Cell Treatment Patent
3. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis
4. FDA Grants Orphan Drug Designation to Omeros OMS721 for Complement-Mediated Thrombotic Microangiopathies
5. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
6. Auxilium Pharmaceuticals, Inc. Announces Court Grants Upsher-Smith Laboratories Motion For Summary Judgment
7. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Aspergillosis
8. RadSite Grants Accreditation to First Wave of MIPPA Program Applicants
9. NASDAQ Grants China Jo-Jo Drugstores 180-Day Extension to Regain Compliance with Bid Price Requirement
10. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
11. FDA Grants 510(k) Clearance for Innovative Fuse Gastroscope from EndoChoice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014  Breckenridge Pharmaceutical, Inc. announced today that ... with Pii (Pharmaceutics International, Inc.) ( Hunt ... Pii expect to develop and commercialize several new ... will develop, manufacture and supply the products, and ... its own label.  The drugs, comprised of four ...
(Date:11/26/2014)... 25, 2014 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... presentations at two upcoming investor conferences.  , 31 ... on Tuesday, December 2, 2014 at 6:45 a.m. EST / ... head of EUSA International, will provide an overview of the company ... Annual Piper Jaffray Healthcare Conference in New York, NY ...
(Date:11/26/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 3, 2014 ... Helen Torley , President and Chief Executive Officer, will provide ... through the "Investors" section of Halozyme,s corporate website at ... 90 days following the event. To access the live webcast, ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
(Date:11/27/2014)... One of the major segments ... for implant dentistry comprises dental implants and abutments ... for dental care is bifurcated into two segments: ... segment is composed of large equipment. , View ... http://www.researchmoz.us/global-dental-market-report-2014-edition-report.html , The worldwide dental market is ...
(Date:11/27/2014)... Today, Digital-Signage-China.com adds 2 new items to its collection of ... player promotion for Dec. 2014. , The CEO of ... April, and this promotion will help to expand our customer ... on our website, she/he can contact us with special need. ... come in the latest designs, and they actually are a ...
(Date:11/27/2014)... Providenciales, Turks and Caicos Islands; BWI (PRWEB) November 28, ... earlier for the Tuscany Resort in the Turks & ... 44 resorts by TripAdvisor in Providenciales, is announcing a ... oceanfront three bedroom villa rentals. And they are ... the resort. , Additionally, The Tuscany, is having ...
(Date:11/27/2014)... 27, 2014 According to a recent ... looking to break into the surgical robotics market ... other than the MIS field dominated by Intuitive. These ... U.S. surgical robotics market by 2020. , “The ... Kamran Zamanian, CEO and President of iData. “System sales ...
(Date:11/27/2014)... Blood-borne pathogens raise the risk of ... procedures in place to counter this. However, it doesn’t ... tainted with menstrual blood are taken as seriously. ... sanitary way to handle tampons and menstrual pads while ... Calif. , He then created a prototype of the ...
Breaking Medicine News(10 mins):Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3Health News:Digital-Signage-China.com Offers Big Discounts On Its New Digital Signage Media Players 2Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2
... Market for EMR and PACS to Reach $9.3 Billion by ... to a new market research report series by iData Research ... market research firm, the U.S. market for Electronic Medical Records ... to more than quadruple in value by 2013. , An ...
... is one of the most vital and dynamic sectors of ... which needs to keep pace with the evolving demands of ... , , New analysis from Frost & Sullivan ( ... Company Profiles , finds that the global medical device market ...
... ... HEALTHeCAREERS Network , ... Englewood, CO (Vocus) July 7, 2009 -- The Texas Hospital Association (THA) ... the state,s hospital members to hundreds of career Web sites., , , , ,"HEALTHeCAREERS ...
... ... Recent data from the Food and Drug Administration’s Adverse Event Reporting System ... disorders reported by users of Reglan (or its generic version, metoclopramide) more ... the manufacturers of Reglan and metoclopramide to add a black-box ...
... July 7 , - Former England ... Rob Hicks, Call on Men to Bat Away Embarrassment and Take,Appropriate ... innings of the Ashes commencing this week, celebrity TV,presenter and former ... to think about their health as well as the Ashes Test,Series ...
... PROVIDE IMMEDIATE BENEFIT TO HEART , A ... to patients. Researchers from the Feinstein Institute for ... biomarkers associated with cardiovascular disease (CVD) in "at ... showed that smoking cessation resulted in significant reductions ...
Cached Medicine News:Health News:iData Research Publishes Market Analysis Series on Electronic Medical Records and PACS 2Health News:Frost & Sullivan Identifies Innovative and Cost-Effective Technology as Key Competitive Factor in European Medical Device Market 2Health News:Frost & Sullivan Identifies Innovative and Cost-Effective Technology as Key Competitive Factor in European Medical Device Market 3Health News:Texas Hospital Association Endorses HEALTHeCAREERS Network 2Health News:Reglan Adverse Events More Than Doubled from 2006 to 2008 2Health News:Reglan Adverse Events More Than Doubled from 2006 to 2008 3Health News:Reglan Adverse Events More Than Doubled from 2006 to 2008 4Health News:Multimedia Release: British Men Think Talking About Impotence is "Just Not Cricket" 2Health News:Multimedia Release: British Men Think Talking About Impotence is "Just Not Cricket" 3Health News:Multimedia Release: British Men Think Talking About Impotence is "Just Not Cricket" 4Health News:Multimedia Release: British Men Think Talking About Impotence is "Just Not Cricket" 5Health News:News briefs from the July issue of CHEST 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: